Cytosorbents (CTSO) Receivables - Other (2017 - 2026)

Cytosorbents' Receivables - Other history runs 10 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• Quarterly Receivables - Other rose 17.71% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 17.71% YoY) and the FY2025 annual result came in at $7.1 million, up 27.23% from the prior year.
• Receivables - Other was $6.9 million for Q1 2026 at Cytosorbents, down from $7.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $7.1 million in Q4 2025 and bottomed at $3.2 million in Q1 2022.
• A 5-year average of $5.2 million and a median of $5.0 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other surged 38.65% — and 2024, when it advanced 5.66%.
• Cytosorbents' Receivables - Other stood at $3.8 million in 2022, then jumped by 38.65% to $5.3 million in 2023, then rose by 5.66% to $5.6 million in 2024, then increased by 27.23% to $7.1 million in 2025, then retreated by 3.16% to $6.9 million in 2026.
• Business Quant data shows CTSO's Receivables - Other at $6.9 million in Q1 2026, $7.1 million in Q4 2025, and $6.0 million in Q3 2025.